Unlocking Potential. Faster.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, oncology, stem cell therapy and unique prescription products. LYMPHIR™ (denileukin diftitox-cxdl), our targeted immune therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) is now approved by the FDA. Commercialization efforts are underway to make this therapy available to patients.
Our team’s extensive experience in the pharmaceutical industry allows us to identify compelling opportunities and develop assets that have unique commercial advantages and differentiated upside potential. By deploying capital thoughtfully, we believe our activities will provide patients and caregivers with improved treatment options and deliver long-term sustainable value to shareholders.